Edgewise Therapeutics Completes Sale of Muscular Dystrophy Program for $1.55B

What Happened Edgewise Therapeutics, Inc. (EWTX) announced on July 13, 2026 (Form 8-K) that it completed the previously announced sale of its sevasemten compound and related muscular dystrophy program to Servier Pharmaceuticals LLC and Les Laboratoires Servier. The Buyers paid $1.55 billion in upfront cash and may pay up to $1.1 billion in future milestone payments, for total potential consideration of up to $2.65 billion. The Company attached a press release about the closing as Exhibit 99.1 and said the Transaction was completed on the terms described in its June 1, 2026 Form 8-K.

Key Details

• Buyers: Servier Pharmaceuticals LLC and Les Laboratoires Servier.
• Upfront cash consideration: $1.55 billion.
• Contingent consideration: up to $1.1 billion in milestone payments (aggregate potential $2.65 billion).
• Filing/notice: Transaction closing announced in 8-K filed July 13, 2026; related prior terms referenced in the June 1, 2026 8-K; press release attached as Exhibit 99.1.
• The Company intends to file required pro forma financial information related to the transaction.

Why It Matters This transaction removes Edgewise’s sevasemten muscular dystrophy program from its pipeline and provides a large immediate cash infusion ($1.55B upfront) plus potential future upside (up to $1.1B in milestones). For investors, that cash can materially affect Edgewise’s balance sheet, liquidity and strategic options going forward, while the milestone structure ties additional value to program development by the Buyers. The company’s forthcoming pro forma financials will clarify the transaction’s accounting and impact on reported results.